Softgel Source, LLC announced a new program for rapid turnaround of low-volume, custom ingestible softgels, offering production priority and no minimum order quantity to facilitate product testing. The initiative aims to support U.S. companies in bringing manufacturing back home and strengthening their competitive position in the marketplace. Kevin McDowell, Founder and CEO of Softgel Source, stated that U.S. companies face both challenges and opportunities in domestic manufacturing. The company's Portland location positions it to help biotech and pharmaceutical businesses rapidly develop and test new softgel products.
This expansion reflects broader trends in U.S. manufacturing, with Deloitte and The Manufacturing Institute projecting continued job growth and biotech manufacturing expected to grow 6–8% annually through 2030. Businesses dependent on offshore manufacturing increasingly face disrupted supply chains, long lead times, and shifting tariffs. McDowell emphasized that manufacturers investing in domestic product development will be best positioned to thrive. Softgel Source helps companies address these issues by offering U.S.-manufactured softgels with fast turnaround rates, serving as both a primary development partner and backup production source when offshore suppliers falter.
The program also addresses regulatory challenges, as constant changes in U.S. and international regulations require companies to reformulate and retest products on short notice. McDowell noted that a local U.S. manufacturer with fast turnaround and low minimum order quantities is ideal for time-sensitive reformulation and testing requirements. More information about the company's services is available at https://softgelsource.com.
Softgel Source focuses on custom softgel manufacturing for vitamin, medication, supplement, and pet product industries, specializing in responsive, rapid turnaround of prototype production and low-to-moderate volume manufacturing for U.S.-based clients. The company's approach supports the growing movement toward domestic manufacturing resilience and regulatory compliance in the ingestible products sector. This development matters because it represents a strategic response to critical vulnerabilities in global supply chains that have disrupted numerous industries in recent years. By eliminating minimum order requirements and prioritizing rapid production, Softgel Source enables smaller companies and startups to compete more effectively while reducing dependency on overseas manufacturing.
The implications extend beyond individual businesses to broader economic and strategic considerations. As biotech manufacturing grows 6–8% annually through 2030 according to industry projections, domestic production capacity becomes increasingly vital for national competitiveness and supply chain security. The program's emphasis on regulatory compliance addresses another significant pain point for companies navigating constantly changing requirements across different markets. This initiative could accelerate reshoring trends in the pharmaceutical and supplement industries while creating a more resilient manufacturing ecosystem less vulnerable to geopolitical tensions, trade disputes, and global disruptions. The availability of flexible, small-batch production with no minimums lowers barriers to innovation, allowing more companies to test new formulations and bring products to market faster while maintaining quality control and regulatory oversight within the United States.
